Caplin Point Lab (CAPLIPOINT)

FairStock Score: 83/100 — HIGH CONVICTION

Score breakdown: P/E: 1/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I view Caplin Point through a Buffett-Graham lens. The financial health is impressive: debt/equity is 0.00, ROE 23.30%, ROCE 25.85%, Piotroski F-Score 8/9 and Altman Z-Score 4.62. That tells me the business earns high returns without leverage, and promoter holding of 70.57% gives strong skin in the game. A debt-free balance sheet adds resilience. Growth is visible: 5-year revenue CAGR of 17.55%, latest quarter sales ₹543 Cr and net profit ₹166 Cr, with sales and profit growth of 184.42% and 108.51%. But those latest growth rates look exceptional; I would not underwrite them as the base case. Free cash flow of ₹99 Cr is positive, yet modest versus the ₹18,855 Cr market cap, so cash conversion matters. Dividend yield is only 0.32%, meaning most returns must come from growth or re-rating. The moat is not obvious from the data, though high ROCE and zero debt suggest some durable advantage. Valuation is where Graham would hesitate. At ₹2480.50, P/E is 28.41, P/B 5.37 and PEG 1.95. The Graham Number is only ₹793.95, giving a margin of safety of -114.13%, while DCF intrinsic value is ₹424.88. Negative EV/EBITDA of -30.23 also needs context. FairStock score of 83/100 signals high conviction, but the price already reflects much of it. I would watch for a wider discount before buying. If I owned it, I would track FCF conversion, growth durability, and whether ROE/ROCE remain above 20%.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer